LONDON, Oct. 18 /CNW/ - Helminth infections are responsible for a huge
health burden on developing country populations, and the number of drugs
available to treat them is incredibly limited.
The paucity of products in development for helminth diseases has
necessitated a focused initiative to boost the R&D pipeline for these
diseases. Consultation meetings organised by the WHO Research and Training in
Tropical Diseases (TDR) Programme in collaboration with the Japanese Society
of Parasitology led to the establishment of the Helminth Drug Initiative
(HDI), which aims to facilitate R&D against human parasitic worm infections.
In a freely available 103-page peer-reviewed special issue of Expert
Opinion on Drug Discovery, the rationale behind the HDI is documented, as well
as reports of technical consultations and recommendations that led to the
initial establishment of the Initiative within TDR.
"The Helminth Drug Initiative is an integral part of an innovative drug
discovery platform established by TDR based on a coordinated network of
partners from industry and academia from the developed and developing
countries", commented Dr Solomon Nwaka, who leads drug discovery efforts and
The special issue focusing on the Helminth Drug Initiative of the Expert
Opinion on Drug Discovery is available for free download at:
About Expert Opinion
The Expert Opinion series provides systematic and authoritative reviews
to support every stage of the drug discovery and R&D pipeline from target to
market. Each of the eleven journals in the series covers a specific aspect of
the pharmaceutical pipeline.
The series contains the following journals: Expert Opinion on Biological
Therapy, Expert Opinion on Drug Delivery, Expert Opinion on Drug Discovery,
Expert Opinion on Drug Metabolism & Toxicology, Expert Opinion on Drug Safety,
Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs,
Expert Opinion on Medical Diagnostics, Expert Opinion on Pharmacotherapy,
Expert Opinion on Therapeutic Patents, and Expert Opinion on Therapeutic
For further information:
For further information: Phil Garner, Publisher, Telephone:
+44-(0)20-7017-6775, Email: firstname.lastname@example.org, Website: